Open AccessEzrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib
Author(s) -
Bülent Çetin,
İpek Işık Gönül,
Özge Gümüşay,
Barış Afşar,
İrem Bilgetekin,
Ahmet Özet,
Aytuğ Üner
Publication year - 2021
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/jcrt.jcrt_372_18
Subject(s) - ezrin , clear cell renal cell carcinoma , sunitinib , medicine , hazard ratio , renal cell carcinoma , oncology , biomarker , proportional hazards model , tyrosine kinase inhibitor , cancer research , urology , cancer , confidence interval , cell , biology , biochemistry , genetics , cytoskeleton
Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. This study evaluates ezrin expression in sunitinib-treated metastatic clear cell renal cell carcinoma (ccRCC) patients and elucidates its role as a possible marker for survival.